Don W. Coulter

Prof. Don W. Coulter

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
Anup S PathaniaAnup S Pathania
Anup S Pathania
HCHaritha Chava
Haritha Chava
NCNagendra Chaturvedi
Nagendra Chaturvedi
SCSrinivas Chava
Srinivas Chava
SBSiddappa Byrareddy
Siddappa Byrareddy
KCKishore Challagundla
Kishore Challagundla
Neuroblastoma (NB) is a highly aggressive pediatric cancer that originates from immature nerve cells, presenting significant treatment challenges due to therapy resistance. Despite intensive treatment, approximately 50% of high-risk NB cases exhibit therapy resistance or experience relapse, resulting in poor outcomes often associated with tumor immune evasion. B7-H3 is an immune checkpoint protein known to inhibit immune responses. MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation. Our study aims to explore the impact of miRNAs on B7-H3 regulation, the anti-tumor immune response, and tumorigenicity in NB. Analysis of NB patients and patient-derived xenograft tumors revealed a correlation between higher B7-H3 expression and poorer patient survival. Notably, deceased patients exhibited a depletion of miR-29 family members (miR-29a, miR-29b, and miR-29c), which displayed an inverse association with B7-H3 expression in NB patients. Overexpression and knockdown experiments demonstrated that these miRNAs degrade B7-H3 mRNA, resulting in enhanced NK cell activation and cytotoxicity. In vivo, experiments provided further evidence that miR-29 family members reduce tumorigenicity, macrophage infiltration, and microvessel density, promote infiltration and activation of NK cells, and induce tumor cell apoptosis. These findings offer a rationale for developing more effective combination treatments that leverage miRNAs to target B7-H3 in NB patients.

3 June 2013 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
MAMelissa A. Acquazzino
Melissa A. Acquazzino
RFRyan T. Fischer
Ryan T. Fischer
ALAlan Langnas
Alan Langnas
DCDon W. Coulter
Don W. Coulter

1 August 2022 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Anup S PathaniaAnup S Pathania
Anup S Pathania
PPPhilip Prathipati
Philip Prathipati
MPManoj K. Pandey
Manoj K. Pandey
SBSiddappa N. Byrareddy
Siddappa N. Byrareddy
DCDon W. Coulter
Don W. Coulter
KCKishore Challagundla
Kishore Challagundla

29 September 2021 in Biomaterials
Verified
Journal Article
Closed access
VKVirender Kumar
Virender Kumar
QWQiyue Wang
Qiyue Wang
BSBharti Sethi
Bharti Sethi
FLFeng Lin
Feng Lin
VKVinod Kumar
Vinod Kumar
RMRam I. I Mahato
Ram I. I Mahato

10 September 2020 in Cancers
Verified
Journal Article
Open access
PDF file
VGVENUGOPAL GUNDA
VENUGOPAL GUNDA
Anup S PathaniaAnup S Pathania
Anup S Pathania
SCSrinivas Chava
Srinivas Chava
PPPhilip Prathipati
Philip Prathipati
NCNagendra Chaturvedi
Nagendra Chaturvedi
KCKishore Challagundla
Kishore Challagundla
Neuroblastoma are pediatric, extracranial malignancies showing alarming survival prognosis outcomes due to their resilience to current aggressive treatment regimens, including chemotherapies with cisplatin (CDDP) provided in the first line of therapy regimens. Metabolic deregulation supports tumor cell survival in drug-treated conditions. However, metabolic pathways underlying cisplatin-resistance are least studied in neuroblastoma. Our metabolomics analysis revealed that cisplatin-insensitive cells alter their metabolism; especially, the metabolism of amino acids was upregulated in cisplatin-insensitive cells compared to the cisplatin-sensitive neuroblastoma cell line. A significant increase in amino acid levels in cisplatin-insensitive cells led us to hypothesize that the mechanisms upregulating intracellular amino acid pools facilitate insensitivity in neuroblastoma. We hereby report that amino acid depletion reduces cell survival and cisplatin-insensitivity in neuroblastoma cells. Since cells regulate their amino acids levels through processes, such as autophagy, we evaluated the effects of hydroxychloroquine (HCQ), a terminal autophagy inhibitor, on the survival and amino acid metabolism of cisplatin-insensitive neuroblastoma cells. Our results demonstrate that combining HCQ with CDDP abrogated the amino acid metabolism in cisplatin-insensitive cells and sensitized neuroblastoma cells to sub-lethal doses of cisplatin. Our results suggest that targeting of amino acid replenishing mechanisms could be considered as a potential approach in developing combination therapies for treating neuroblastomas.

15 December 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DKDEVENDRA KUMAR
DEVENDRA KUMAR
SJStuti Jain
Stuti Jain
DCDon W. Coulter
Don W. Coulter
SJShantaram S. Joshi
Shantaram S. Joshi
NCNagendra Chaturvedi
Nagendra Chaturvedi
MYC amplification or overexpression is most common in Group 3 medulloblastomas and is positively associated with poor clinical outcomes. Recently, protein arginine methyltransferase 5 (PRMT5) overexpression has been shown to be associated with tumorigenic MYC functions in cancers, particularly in brain cancers such as glioblastoma and medulloblastoma. PRMT5 regulates oncogenes, including MYC, that are often deregulated in medulloblastomas. However, the role of PRMT5-mediated post-translational modification in the stabilization of these oncoproteins remains poorly understood. The potential impact of PRMT5 inhibition on MYC makes it an attractive target in various cancers. PRMT5 inhibitors are a promising class of anti-cancer drugs demonstrating preclinical and preliminary clinical efficacies. Here, we review the publicly available preclinical and clinical studies on PRMT5 targeting using small molecule inhibitors and discuss the prospects of using them in medulloblastoma therapy.